Ardelyx, Inc.
(NASDAQ : ARDX)

( )
ARDX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
-0.31%86.001.3%$1325.78m
AMGNAmgen Inc.
-0.93%201.981.2%$608.04m
GILDGilead Sciences, Inc.
-0.91%68.550.9%$534.22m
LOXOLoxo Oncology Inc
0.12%233.7812.7%$511.41m
BIIBBiogen Inc.
0.46%338.961.3%$413.85m
VRTXVertex Pharmaceuticals Incorporated
-0.42%193.881.9%$324.40m
ILMNIllumina, Inc.
-2.92%303.623.5%$304.88m
REGNRegeneron Pharmaceuticals, Inc.
-3.36%404.752.6%$294.14m
ALXNAlexion Pharmaceuticals, Inc.
-2.36%114.292.0%$213.93m
INCYIncyte Corporation
-1.39%77.332.5%$145.56m
AAgilent Technologies, Inc.
-0.89%71.291.5%$145.13m
EXASExact Sciences Corporation
-3.46%76.0725.3%$135.78m
SRPTSarepta Therapeutics, Inc.
-2.05%120.2815.4%$130.09m
LGNDLigand Pharmaceuticals Incorporated
-4.23%112.9123.1%$119.15m
NBIXNeurocrine Biosciences, Inc.
-0.27%91.285.1%$97.05m

Company Profile

Ardelyx, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicine for the treatment of renal diseases. It also focuses on the development of programs directed toward treating gastrointestinal and irritable bowel syndrome with constipations. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Fremont, CA.